ESR1 and breast cancer: In addition, in tumors showing a triple-negative phenotype (ER− PR− HER2−) ATIP3 levels are significantly lower than those measured in luminal (ER+) and HER2+, suggesting that ATIP3 may represent a novel molecular marker for poor outcome of breast cancer.